Small Stocks, Big Money™

Can-Fite BioPharma (NYSE American: CANF) has received Institutional Review Board (IRB) approval from Rabin Medical Center for a Phase IIa study of Namodenoson in treating advanced pancreatic cancer. The study aims to assess the safety and efficacy of Namodenoson in patients whose cancer has progressed despite first-line treatment. Positive preclinical and Phase II liver cancer data prompted this trial. The open-label study will involve 20 patients, evaluating safety and clinical activity, including overall survival. The study is led by Dr. Salomon Stemmer at Rabin Medical Center, with findings published in peer-reviewed journals highlighting Namodenoson’s molecular mechanisms and efficacy.

Spectaire Holdings Inc. (Nasdaq: SPEC) has integrated its advanced AireCore mass spectrometers into American Ag Energy's biomass-to-fuel reactors, enhancing their efficiency and market reach. The initial order and delivery of AireCore units were completed in May 2024. This collaboration allows American Ag Energy to precisely tune their reactors, boosting fuel production and operational efficiency in the $91 billion biomass energy market.

60 Degrees Pharmaceuticals (Nasdaq: SXTP) has secured FDA orphan drug designation for tafenoquine to treat acute babesiosis, a tick-borne illness. ODD qualifies tafenoquine for incentives like market exclusivity, tax credits, and fee exemptions. The company will conduct the first clinical trial on tafenoquine for babesiosis with Tufts Medical Center, starting in June 2024, involving 24 patients. Babesiosis, transmitted by ticks, poses severe risks, especially to immunosuppressed individuals. CEO Geoff Dow highlights tafenoquine's potential, supported by promising animal studies, as a crucial treatment for this emerging infectious disease.

Sharps Technology (Nasdaq: STSS) received a $30 million purchase order from Nephron Pharmaceuticals for 10mL and 50mL specialty copolymer prefillable syringes. This order marks the first order of their five-year, $200 million syringe sales agreement. The syringes are expected to begin shipping to customers from Sharps’ new facility in West Columbia, SC, starting in Q2 2025. Sharps' advanced polymer syringes offer improved safety, durability, and compatibility with modern drug therapies over traditional glass syringes. The acquisition of the SC facility, projected to close by the end of July, is expected to drive over $35 million in revenue in the first year, with potential growth to $100 million annually by 2028.